These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34054051)

  • 1. A Feasibility Pilot Study of Online Modules of Hydroxyurea and Sickle Cell Disease Care for Adolescents and Young Adults for Family Medicine Residents.
    Dawson A; Mullen K; Janson IA; Henriksen B; Duncan N; O'Brien D; Meier ER
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e313-e318. PubMed ID: 34054051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease.
    Badawy SM; Thompson AA; Liem RI
    Pediatr Blood Cancer; 2016 May; 63(5):848-52. PubMed ID: 26844685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey.
    Askew MA; Smaldone AM; Gold MA; Smith-Whitley K; Strouse JJ; Jin Z; Green NS
    Pediatr Blood Cancer; 2022 Oct; 69(10):e29877. PubMed ID: 35856776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
    Su ZT; Segal JB; Lanzkron S; Ogunsile FJ
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
    Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
    JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.
    Reddy PS; Cai SW; Barrera L; King K; Badawy SM
    Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
    Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
    Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No child left behind: Building a comprehensive sickle cell disease care oasis in the Lake County, Indiana care desert.
    Brown LC; Hampton KC; Bloom EM; Lawson D; Cooper SH; Meier ER
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29619. PubMed ID: 35441446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
    Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI
    Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE; Nevitt SJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
    Dexter D; McGann PT
    Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
    Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
    JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Satisfaction and access to care for adults and adolescents with sickle cell disease: ASCQ-Me quality of care and the SHIP-HU study.
    Sisler I; McClish DK; Valrie C; Villella A; Smith WR
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29948. PubMed ID: 36151945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.